期刊
CANCER DISCOVERY
卷 7, 期 2, 页码 137-155出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-16-1123
关键词
-
类别
资金
- NCI [5R01CA164273]
- National Foundation for Cancer Research
- Be a Piece of the Solution
- LungStrong
- Evan Spirito Foundation
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK rearranged malignancies, including non-small cell lung cancer. However, the clinical benefi t of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance. Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic. In this review, we summarize the current successes and challenges of targeting ALK. Significance: Effective long-term treatment of ALK-rearranged cancers requires a mechanistic understanding of resistance to ALK TKIs so that rational therapies can be selected to combat resistance. This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms. Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome. (C) 2017 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据